Anthera Pharmaceuticals Articles
Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity
4 April 2013
Barriers to overcome in lupus drug development
22 July 2012
Anthera tanks as it halts Ph III heart drug trial
12 March 2012
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
